Johnson & Johnson: EPS up to $2.20 in Q1

(CercleFinance.com) - Sales grew by 2.
3% to $21.4bn in Q1 2024, with operating up 3.9% and adjusted operating increasing 4.0%.

Excluding the COVID-19 vaccine, Q1 2024 EPS rose to $2.20 and adjusted EPS increased to $2.71, up 12.4%.

Johnson & Johnson's strong first-quarter performance reflects its increased focus and progress in its portfolio and pipeline, it said.

Our impact across the healthcare spectrum is unique in our industry, and the milestones achieved this quarter reinforce our position as an innovation powerhouse.

For 2024, J&J says it is now targeting sales growth of 5.5% to 6%, with EPS expected between $10.60 and $10.75, taking into account the dilutive effect of the Laminar acquisition.


Copyright (c) 2024 CercleFinance.com. All rights reserved.